e-learning
resources
Vienna 2003
Sunday 28.09.2003
Pathophysiology of the pulmonary circulation
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension
R. T. Schermuly, K. P. Kreisselmeier, A. Ghofrani, N. Weissmann, F. Rose, C. Schudt, W. Seeger, F. Grimminger (Giessen, Konstanz, Germany)
Source:
Annual Congress 2003 - Pathophysiology of the pulmonary circulation
Session:
Pathophysiology of the pulmonary circulation
Session type:
Oral Presentation
Number:
264
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. T. Schermuly, K. P. Kreisselmeier, A. Ghofrani, N. Weissmann, F. Rose, C. Schudt, W. Seeger, F. Grimminger (Giessen, Konstanz, Germany). Effects of iloprost and the phosphodiesterase inhibitor tolafentrine on pulmonary vascular remodelling in chronic experimental pulmonary hypertension. Eur Respir J 2003; 22: Suppl. 45, 264
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
From pulmonary gas exchange to the interpretation of arterial blood gases
The physiology of breathlessness
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension
Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases
Year: 2009
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Sildenafil enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 24s
Year: 2002
Inhaled iloprost reverses chronic experimental pulmonary hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 353s
Year: 2005
Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension
Source: Eur Respir J 2001; 18: Suppl. 33, 198s
Year: 2001
HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2006 Oct 01;28(4):691-694
Year: 2006
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil
Source: Eur Respir J 2010; 36: 800-807
Year: 2010
2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Effect of roflumilast on hypoxia- and monocrotaline-induced pulmonary hypertension in rats
Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair
Year: 2007
2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007
Effect of PDE-5 inhibitor treatment in patients with interstitial lung disease and pulmonary hypertension
Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases
Year: 2011
Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 1354-1360
Year: 2009
Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension
Source: Eur Respir J 2002; 20: 339-343
Year: 2002
Comparison of acute hemodynamic effects of three different phosphodiesterase inhibitors in patients with pulmonary arterial hypertension
Source: Eur Respir J 2004; 24: Suppl. 48, 705s
Year: 2004
Phosphodiesterase-type 3 inhibitor potentiates cAMP generation and antiproliferative effects of treprostinil in pulmonary arterial smooth muscle cells from patients with pulmonary hypertension
Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension
Year: 2010
Predictors of response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension
Source: Virtual Congress 2021 – Therapy of pulmonary hypertension
Year: 2021
Long-term treatment of pulmonary hypertension with aerosolized iloprost
Source: Eur Respir J 2001; 17: 8-13
Year: 2001
ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Sildenafil is a potent pulmonary vasodilator in pulmonary hypertension associated with interstitial lung disease: impact on gas exchange properties
Source: Eur Respir J 2002; 20: Suppl. 38, 598s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept